Community-Based Practice Variations in Topical Treatment of Actinic Keratoses.
Authors:
Open Access
- 1 May 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (5) , 468-470
Abstract
Actinic keratoses (AKs) are precancerous skin lesions afflicting nearly 58 million people in the United States per year and costing over a billion dollars annually to treat.1,2 Two of the most widely used topical field-based treatments for AKs are fluorouracil and imiquimod.3 Although variations exist in how these topical medications are prescribed in terms of frequency, duration, and strength for AK treatment,4 no studies have systematically examined how patient and health care provider factors impact prescribed regimens. Using data from a large community-based population, we examined how variations in fluorouracil and imiquimod prescription patterns for AKs treatment was influenced by patient age, sex, AK anatomic site, and prescriber type.Keywords
This publication has 4 references indexed in Scilit:
- Primary Care Review of Actinic Keratosis and Its Therapeutic Options: A Global PerspectiveDermatology and Therapy, 2015
- Top dermatologic diagnoses by ageDermatology Online Journal, 2014
- The burden of skin diseases: 2004Journal of the American Academy of Dermatology, 2006
- Predictors of treatment choices and associated outcomes in actinic keratoses: Results from a national physician survey studyJournal of Dermatological Treatment, 2006